Jubilant Life Sciences has received Abbreviated New Drug Application (ANDA) final approval for Rosuvastatin Calcium Tablets, 5 mg, 10 mg, 20 mg and 40 mg, the generic version of Crestor of IPR Pharmaceuticals, which is used for the treatment of hyperlipidemia or mixed dyslipidemia.
The company has received 7 approvals from the USFDA during the year. As on September 30, 2016, it had a total of 72 ANDAs for Oral Solids filed in the US, of which 47 have been approved.
Jubilant Life Sciences is an integrated global Pharmaceutical and Life Sciences Company engaged in manufacture and supply of APIs, Solid Dosage Formulations, Radiopharmaceuticals, Allergy Therapy Products and Life Science Ingredients.
